Aastrom Biosciences, Inc. develops patient-specific cell products for treating severe, chronic ischemic cardiovascular diseases. The company is developing ixmyelocel-T, a multicellular therapy expanded from a patient’s own bone marrow and delivered directly to damaged tissues. Ixmyelocel-T is in late-stage clinical … Continue reading →

Cancer Genetics, Inc. is an early-stage diagnostics company developing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis, and response to the treatment of cancer. The company’s tests target many cancers, including hematological, urogenital, and HPV-associated cancers. … Continue reading →

Oxygen Biotherapeutics, Inc. is a development stage company developing biotechnology products that deliver oxygen to target tissues in the body. The company develops Oxycyte, an oxygen carrier for use in situations of acute ischemia, which is in clinical trial for … Continue reading →

Invivo Therapeutics Holdings Corp. (OTCBB: NVIV) is a development stage company engaged in the development and commercialization of biopolymer scaffolding devices for the treatment of spinal cord injuries, peripheral nerve injuries, and other neurotrauma conditions. The company also aims to … Continue reading →

Amarin Corporation plc is a biopharmaceutical company engaged in developing and bringing to market therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and the therapeutic benefits of polyunsaturated fatty acids. The company’s … Continue reading →

Organovo Holdings, Inc. develops three-dimensional (3D) bioprinting technology for creating functional human tissues for research and medical applications. The company’s 3D NovoGen bioprinting technology works across various tissue and cell types, and allows for the placement of cells in desired … Continue reading →

BioSpecifics Technologies Corp. (NASDAQ: BSTC) is a biopharmaceutical company that is focused on developing an injectable collagenase for various clinical indications. Under the XIAFLEX name, BioSpecifics provides injectable collagenase for the treatment of adult Dupuytren’s contracture patients with a palpable … Continue reading →

Venaxis, Inc. develops and commercializes products for unmet diagnostic and therapeutic needs. Its lead product candidate includes APPY1, a blood-based diagnostic test designed to aid in the evaluation of patients for acute appendicitis. The company, through its license agreement with … Continue reading →

SciClone Pharmaceuticals, Inc. provides therapies for the treatment of oncology, infectious diseases, cardiovascular, urological, respiratory, and central nervous system disorders in China and internationally. Its principal product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis … Continue reading →

Acorda Therapeutics, Inc. is a commercial-stage biopharmaceutical company that engages in identifying, developing and bringing to market therapies for multiple sclerosis (MS), spinal cord injury and other central nervous system disorders. Acorda’s products include: Ampyra (dalfampridine), a potassium channel blocker for improving … Continue reading →